Illumina Settles One Patent Dispute With Qiagen; Faces Separate Suit From Columbia, Qiagen

Qiagen

NEW YORK (GenomeWeb) – Illumina has settled one patent infringement lawsuit with Qiagen over next-generation sequencing technology, but faces a separate suit from Columbia University, which has sued it for infringing a recently awarded patent exclusively licensed to Qiagen.

In last week’s settlement of an ongoing case in the US District Court for the Northern District of California, Qiagen agreed not to sell its GeneReader and reagents in the US. However, as Qiagen announced last year, it has been developing a new chemistry based on different technology than is included in the settled litigation, and currently offers the upgraded chemistry with the GeneReader for US customers

John Gilardi, vice president and head of corporate communications and investor relations for Qiagen, said that the company is “pleased with the settlement.” However, given that Qiagen had already upgraded its chemistry, “this settlement does not change our ability to offer the new chemistry to customers and the benefits of the GeneReader NGS system, and we continue to believe that we have freedom to operate.”

He added that the firm plans to launch five new panels this year for breast, ovarian, and lung cancer, and will also offer the chemistry upgrade to customers in other countries.

Gilardi declined to comment on the new patent infringement suit brought by Columbia and Qiagen against Illumina. In that suit, filed in the US District Court for the District of Delaware, the plaintiffs allege that Illumina’s NGS systems and reagents infringe US Patent No., 9,708,358, “Massive Parallel Method for Decoding DNA and RNA,” which was issued to Columbia earlier this month and which Qiagen exclusively licenses.

Specifically, the patent covers nucleotide analogues that can be used in sequencing-by-synthesis reactions, including the use of modified nucleotides with removable caps and detectable labels.

In the suit, the plaintiffs request damages for the alleged infringement, including royalties, as well as an injunction that prohibits Illumina from selling instruments and reagents that infringe, and payment of attorney’ fee.

 

Full Article Here

Submit a Comment

Your email address will not be published.

Subscribe to get the latest news